{"id":"cefazolin-and-indomethacin","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Hypersensitivity reactions (rash, anaphylaxis)"},{"rate":"5-15","effect":"Gastrointestinal upset (nausea, dyspepsia)"},{"rate":"1-5","effect":"Renal impairment"},{"rate":"1-3","effect":"Bleeding risk (indomethacin)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cefazolin is a first-generation cephalosporin that binds to penicillin-binding proteins and disrupts bacterial cell wall cross-linking, leading to cell lysis and death. Indomethacin is a non-selective cyclooxygenase (COX) inhibitor that reduces prostaglandin production, thereby decreasing inflammation, pain, and fever. This combination is typically used perioperatively to provide both antimicrobial coverage and anti-inflammatory/analgesic effects.","oneSentence":"This combination uses cefazolin (a beta-lactam antibiotic) to inhibit bacterial cell wall synthesis and indomethacin (an NSAID) to reduce inflammation and inhibit prostaglandin synthesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:43:21.464Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Surgical site infection prophylaxis and perioperative pain/inflammation management"}]},"trialDetails":[{"nctId":"NCT05132829","phase":"PHASE4","title":"Azithromycin to Improve Latency in Exam Indicated Cerclage Control Trial","status":"UNKNOWN","sponsor":"Thomas Jefferson University","startDate":"2021-12-20","conditions":"Preterm Birth, Obstetric Labor, Premature, Obstetric Labor Complications","enrollment":50},{"nctId":"NCT04766996","phase":"PHASE4","title":"PROUD Study - Preventing Opioid Use Disorders","status":"TERMINATED","sponsor":"Emory University","startDate":"2021-05-17","conditions":"Anesthesia, Opioid Use","enrollment":57},{"nctId":"NCT01114516","phase":"NA","title":"Multifactorial Approach to Emergent Cerclage","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2010-03","conditions":"Cervical Insufficiency","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cefazolin and indomethacin","genericName":"Cefazolin and indomethacin","companyName":"Thomas Jefferson University","companyId":"thomas-jefferson-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses cefazolin (a beta-lactam antibiotic) to inhibit bacterial cell wall synthesis and indomethacin (an NSAID) to reduce inflammation and inhibit prostaglandin synthesis. Used for Surgical site infection prophylaxis and perioperative pain/inflammation management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}